Seralutinib
Phase 3Active 0 watching 0 views this week📈 Rising
69
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Pulmonary Arterial Hypertension
Conditions
Pulmonary Arterial Hypertension
Trial Timeline
Sep 3, 2024 → Dec 1, 2026
NCT ID
NCT06274801About Seralutinib
Seralutinib is a phase 3 stage product being developed by Gossamer Bio for Pulmonary Arterial Hypertension. The current trial status is active. This product is registered under clinical trial identifier NCT06274801. Target conditions include Pulmonary Arterial Hypertension.
Hype Score Breakdown
Clinical
27
Activity
18
Company
2
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06274801 | Phase 3 | Active |
Competing Products
20 competing products in Pulmonary Arterial Hypertension